STAAR Surgical

STAAR Surgical Co. engages in the development, manufacture, production, marketing, and sale of implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It specializes in refractive and cataract solutions. Its products include intraocular lens and implantable collamer lens. The company was founded in 1982 and is headquartered in Lake Forest, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

STAAR Surgical reports robust Q4 performance and eyes U.S. growth

STAAR Surgical's Q4 2022 earnings call highlighted strong performance, growth opportunities in key markets, and strategic investments for future success. Despite challenges in China, the company remains optimistic about market recovery and growth prospects. With a focus on EVO lens adoption and increased investments, STAAR is well-positioned for continued growth and market expansion.

STAAR Surgical excels in Q1 with strong global sales growth

STAAR Surgical's Q1 2023 earnings call highlighted robust global sales growth, positive market reception, and strategic investments for future expansion. The company aims to strengthen its market position through targeted growth strategies and operational enhancements.

STAAR Surgical reports record Q2 sales, eyes global expansion

STAAR Surgical's Q2 2023 performance showcased record sales and growth, driven by the EVO family of ICLs.
The company's strong presence in APAC, particularly China, and confidence in high-growth outlook are notable.
Challenges include market declines and pricing dynamics, but opportunities lie in global expansion and strategic initiatives.
Balancing growth and profitability remains a focus, with ongoing efforts to enhance market presence and address challenges.

STAAR Surgical reports resilient Q3 performance amidst market challenges

STAAR Surgical's Q3 2023 performance reflects continued growth in ICL sales despite challenges.
The company is navigating macroeconomic headwinds while focusing on market-building initiatives.
Despite a decline in operating income, STAAR remains confident in its growth prospects.
STAAR's strategic focus on new products and market expansion positions it for future success.

STAAR Surgical posts robust Q4 results, eyes global expansion opportunities

STAAR Surgical's strong financial performance and strategic initiatives position the company for continued growth and market leadership.
Challenges from market competition and macroeconomic factors require careful navigation, but opportunities in expanding markets and operational enhancements offer avenues for growth.
With a focus on innovation, profitability, and global expansion, STAAR is poised to capitalize on market trends and drive sustainable growth in the coming years.

STAAR Surgical surpasses Q1 sales targets, eyes global expansion

STAAR Surgical's Q1 2024 performance exceeded expectations, driven by strong global sales growth and strategic milestones. Challenges include addressing discrepancies in sales and unit growth. The company is poised to capitalize on opportunities in China, surgeon training, and international expansion.

STAAR Surgical posts robust Q2 results, eyes global expansion

STAAR Surgical's Q2 2024 performance reflects strong sales growth, improved profitability, and a positive outlook for fiscal 2024.
The company's strategic strengths in global market expansion and innovation position it well for future growth and achieving long-term sales targets.
Challenges in managing operating expenses and sustaining growth rates in key markets require continued strategic focus and operational efficiency.
Opportunities in expanding market presence, driving innovation, and leveraging financial strength present avenues for sustained growth and market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

STAAR Surgical Co. engages in the design, development, manufacture, and sale of ophthalmic surgical products. The firm offers implantable lenses for the eye and accessory delivery systems. Its products include refractive and cataract solutions through the Collamer brand. The company was founded in 1982 and is headquartered in Lake Forest, CA.

New York, New York--(Newsfile Corp. - August 17, 2020) -  Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA).If you invested in STAAR stock or options and would like to discuss your legal rights, click here: w

STAAR Investor Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In STAAR Surgical Company To Contact The Firm

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of STAAR Surgical Company (NASDAQ: STAA) resulting from allegations that STAAR may have issued materially misleading business information to the investing public. On August 11, 2020, the investment analyst J Capital issued a report on STAAR entitled "STARR Surgical, Less Than Meets the Eye.

EQUITY ALERT: ROSEN, A LEADING AND RANKED LAW FIRM, Announces Investigation of Securities Claims Against STAAR Surgical Company – STAA

LOS ANGELES--(BUSINESS WIRE)---- $STAA #classaction--The Law Offices of Frank R. Cruz announces an investigation on behalf of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA) investors concerning the Company’s possible violations of federal securities laws.

The Law Offices of Frank R. Cruz Announces Investigation of STAAR Surgical Company (STAA) on Behalf of Investors

STAAR Surgical Company (STAA) CEO Caren Mason on Q2 2020 Results - Earnings Call Transcript

Staar Surgical (STAA) delivered earnings and revenue surprises of -25.00% and -6.40%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Staar Surgical (STAA) Misses Q2 Earnings and Revenue Estimates

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today reported financial results for the second quarter ended July 3, 2020.

STAAR Surgical Reports Second Quarter 2020 Results

STAAR Surgical's (STAA) ICL line of products is likely to have boosted Q2 performance amid the coronavirus pandemic.

STAAR Surgical (STAA) to Report Q2 Earnings: What's in Store?

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release financial results for the second quarter ended July 3, 2020 on Wednesday, August 5, 2020 after the market close.

STAAR Surgical to Report Second Quarter Results on August 5, 2020

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA) today announced that to support the health and well-being of its shareholders, employees, directors, and communities due to the public health threat of the COVID-19 pandemic the Company’s upcoming 2020 Annual Meeting of Shareholders (the “Annual Meeting”) will be held in a virtual-only format. As previously announced, the Annual Meeting will be held on Thursday, July 30, 2020, at 8:30 a.m. PT, but shareholders will not

STAAR Surgical Company to Hold 2020 Annual Meeting of Shareholders in Virtual Format

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that EVO Viva™, STAAR’s innovative presbyopia correcting implantable Collamer® lens (“ICL”), has been approved for sale. STAAR received CE Mark approval of the presbyopic indication for its EVO+ Visian® ICL with Aspheric (EDOF) Optic, commercially marketed as “EVO Viva”, from its European Not

STAAR Surgical Introduces EVO Viva™ Presbyopia Correcting Lens – See Young Again!

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that Patrick F. Williams has joined the Company as Chief Financial Officer effective today. Mr. Williams is reporting to Caren Mason, President and Chief Executive Officer. His appointment is part of a planned transition following Deborah Andrews’ previously announced retirement. Ms. Andrews

Patrick F. Williams Appointed Chief Financial Officer of STAAR Surgical

STAAR Surgical (STAA) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

STAAR Surgical (STAA) Jumps: Stock Rises 8.9%

STAAR Surgical Co (STAA) CEO Caren Mason on Q1 2020 Results - Earnings Call Transcript

Staar Surgical (STAA) delivered earnings and revenue surprises of -42.86% and 5.04%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Staar Surgical (STAA) Q1 Earnings Lag Estimates

STAAR Surgical Company (STAA) CEO Caren Mason on Q4 2019 Results - Earnings Call Transcript

STAAR Surgical: Bullish Following Investor Day Updates

STAAR Surgical Company (STAA) CEO Caren Mason on Q3 2019 Results - Earnings Call Transcript

Staar Surgical (STAA) delivered earnings and revenue surprises of 33.33% and 4.15%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Staar Surgical (STAA) Beats Q3 Earnings and Revenue Estimates

Great second-quarter earnings results sent the implantable contact lens maker's stock into orbit.

Why STAAR Surgical Stock Is Skyrocketing Today

STAAR Surgical Company (STAA) CEO Caren Mason on Q2 2019 Results - Earnings Call Transcript

Staar Surgical (STAA) delivered earnings and revenue surprises of 40.00% and -1.09%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Staar Surgical (STAA) Beats Q2 Earnings Estimates

Staar Surgical (STAA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Staar Surgical (STAA) Reports Next Week: Wall Street Expects Earnings Growth

Stock fell as much 22% on news the FDA rejected its application to market 'EVO' lenses in the United States.

STAAR Surgical Company: Down On FDA Disclosure, But Not Out

Clean Harbors

Great Lakes Dredge & Dock

Herman Miller

New job additions across business services, construction and healthcare were prominent in April.

4 Stocks to Buy From Sectors With Top Job Gains

STAAR Surgical Company (STAA) CEO Caren Mason on Q1 2019 Results - Earnings Call Transcript

News for STAAR Surgical Stock (STAA)